Skip to main content

Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays



α-Synuclein is a small soluble protein, whose physiological function in the healthy brain is poorly understood. Intracellular inclusions of α-synuclein, referred to as Lewy bodies (LBs), are pathological hallmarks of α-synucleinopathies, such as Parkinson’s disease (PD) or dementia with Lewy bodies (DLB).

Main body

Understanding of the molecular basis as well as the factors or conditions promoting α-synuclein misfolding and aggregation is an important step towards the comprehension of pathological mechanism of α-synucleinopathies and for the development of efficient therapeutic strategies. Based on the conversion and aggregation mechanism of α-synuclein, novel diagnostic tests, such as protein misfolding seeded conversion assays, e.g. the real-time quaking-induced conversion (RT-QuIC), had been developed. In diagnostics, α-synuclein RT-QuIC exhibits a specificity between 82 and 100% while the sensitivity varies between 70 and 100% among different laboratories. In addition, the α-synuclein RT-QuIC can be used to study the α-synuclein-seeding-characteristics of different α-synucleinopathies and to differentiate between DLB and PD.


The variable diagnostic accuracy of current α-synuclein RT-QuIC occurs due to different protocols, cohorts and material etc.. An impact of micro-environmental factors on the α-synuclein aggregation and conversion process and the occurrence and detection of differential misfolded α-synuclein types or strains might underpin the clinical heterogeneity of α-synucleinopathies.


α-Synucleinopathies, such as Parkinson’s disease (PD), dementia with Lewy bodies (DLB) or multiple system atrophy (MSA), are a class of neurodegenerative diseases characterized by the presence of misfolded, fibrillary α-synuclein. In PD and DLB, the deposits of α-synuclein (Lewy bodies, (LBs)) occur intracellular within neurons, while MSA patients show oligodendroglial cytoplasmic inclusions (GCI), called Papp-Lantos bodies, rather than neuronal aggregates.

Even though the cellular distribution of aggregated α-synuclein is different, there is a significant pathological overlap. In both diseases, neurodegeneration is associated with the LBs and GCI burden, as well as the increase of soluble α-synuclein in substantia nigra and striatum [1]. In addition, there is an apparent overlap in degeneration of the dopaminergic nigrostriatal system in PD and MSA. The folding process of a protein (e.g. α-synuclein) occurs in dependence on its energetic landscape, defined by the thermodynamic constrictions that force it to assume the conformation of the lowest free energy. Whereas protein folding is regulated mostly by chaperones [2, 3], a class of proteins called intrinsically disordered proteins (IDPs, such as α-synuclein), which owns a low complexity region that may adopt an alternative, β-sheets enriched conformation [4,5,6,7], show poor binding features to chaperones [8,9,10,11]. IDPs may form fibrils and plaques [12], characterized by a β-sheet conformation with β-strands perpendicular to the length of the fibril, favoured by an exclusion of water from the inner core of the fibril and hydrophobic interactions. The summation of all forces enables the misfolded protein to cross its metastable intermediate stages and lean toward the minimal energy level of the misfolded amyloid [13]. Whereas equilibrium among the native and the intermediate stages (which may be populated by oligomers) is possible, the formation of amyloids represents an irreversible process. Previous studies indicate that the misfolding and subsequent conversion of one or more proteins into a pathogenic variant may contribute to the onset of neurodegenerative diseases, retracing the protein-only hypothesis originally formulated for the prion protein [14,15,16,17]. According to this view, the propagation of misfolded proteins requires the formation of a homotypic complex between the two conformers of a protein [17], which leads to the conversion of the native form into the pathogenic form. The novel β-sheet-enriched molecule may act as a seed, contacting other native molecules (typically referred as substrate) and imposing the conversion into β-sheets, establishing a positive feedback that eventually causes the aggregation into plaques and fibrils.

In this review we focus on α-synuclein, a protein whose intracellular aggregates are hallmarks in α-synucleinopathies. At first, we discuss the potential prion-like conversion behaviour of α-synuclein. Afterwards, we summarize the micro-environmental factors that may affect the α-synuclein aggregation process and their impact on the diagnostic performance of major techniques based on the seed-mediated conversion of misfolded species of α-synuclein. At last, we review the state of the art about the existence and the impact of different synuclein strains that may contribute to different clinical features in α-synucleinopathies.

Main text

Conversion and transmission of misfolded α-synuclein

Being a natively unfolded protein [18], α-synuclein aggregation is ruled by thermodynamics [19]. The first event in the assembly of α-synuclein is supposed to be dimerization [20], leading in turn to the generation of aggregation-competent oligomers, encompassing a wide variety of structures [21], and possessing their own kinetics of fibrillization and toxicity [22].

The conversion behaviour of α-synuclein, described as “prion-like”, has been reported by evidences of graft-to-host spreading of α-synuclein aggregates [23,24,25]. Aggregated α-synuclein can be transmitted from neuron to neuron [26] either after neuronal death or by exocytosis-mediated pathways [26], while the uptake may occur be endocytic pathways [27], substantiating the neuron-to-neuron transmission and the predictable spreading observed in some forms of α-synucleinopathies. Recently, α-synuclein was shown to interact with high density lipoproteins [28] and the presence of α-synuclein, both in its native and misfolded conformation, was found in extracellular vesicles as well [29, 30], suggesting a potential novel route for the spreading of the pathology. Moreover, α-synuclein transmission along axonal connections was demonstrated ex vivo and in vivo in various animal models.

Luk and co-workers demonstrated that fibrillary α-synuclein is able to trigger the conversion of monomeric α-synuclein into aggregates closely reminiscent of LBs and neurites in a cell model overexpressing α-synuclein [31]. Fibrillary α-synuclein was further found to be transported anterogradely through the axon and taken up by the next neuron in mouse embryonic cultures [32], while in vivo studies conducted with rats showed the trans-neuronal spreading of fibrils from the olfactory bulb toward other non-olfactory regions [33]. The transport of fibrillary α-synuclein forms were shown to follow an anterograde pathway through the axon and passaged to the next neuron in mouse embryonic cultures. Moreover, in vivo studies conducted in rats demonstrated that α-synuclein fibrils spread from the olfactory bulb toward other non-olfactory regions [33]. Others showed that α-synuclein aggregates were inoculated in the medulla oblongata of rats, and the caudo-rostral spreading was followed by showing fibers and neuronal abnormalities in the rostral mesencephalon and in prosencephalic regions after 18 weeks [34]. Lastly, PD pathology was successfully passaged to non-human primates by administration of human PD-derived LBs.

The spreading of α-synuclein through different routes may highlight the differential affinity of different cell types toward α-synuclein binding and internalization, as the cellular milieu differs among populations of cells derived from different developmental lineages. Thus, the cellular environment may play an instructive role for the spreading of misfolded α-synuclein, affecting first highly vulnerable cell lineages.

In the next section, we will address the environmental factors that may affect the aggregation of α-synuclein, its seeding ability and thus the modes of spreading through various routes.

Micro-environmental factors affecting the α-synuclein aggregation

A plethora of environmental factors have been found to affect protein misfolding and aggregation [35]. Physical factors, such as molecular crowding and temperature, may affect protein aggregation by enhancing the entropy of the system. Similarly, chemical factors such as pH variations or the presence of other proteins or biomolecules, such as nucleic acids, phospholipids and proteoglycans, may affect the aggregation process. Moreover, post-translational modifications (PTMs) may also interfere with the aggregation process by affecting the surface charge or the topology of the protein. The effect of these conditions on α-synuclein aggregation is summarized in Table 1.

Table 1 Factors affecting α-synuclein aggregation. The table summarizes the effects of various chemical, physical and biological agents on α-synuclein aggregation. Effect is either defined as enhancing when promotes the aggregation or quenching when it slows down the aggregation. The rationale for the effect is listed in the table as well.

Additional, often overlooked factors in PD patients, which influence the misfolding and aggregation features of α-synuclein, are missense point mutations in the α-synuclein gene (SNCA) (e.g. A53T, A53E) as well as the potential increase of α-synuclein expression levels, induced by duplications or triplications of SNCA. The genetic A53T missense mutation causes conformational changes in α-synuclein with structural alterations of the β-sheet structures, thermodynamically more stable in aqueous solutions, exhibiting a significant influence on the aggregation process [36]. Experimentally, the integration of a genetic PD associated point mutation in recombinant α-synuclein substrate would accelerate the seeding response of oligomeric α-synuclein in seeded aggregation assays. However, it may also promote the self-aggregation of the substrate and the generation of false-positives, as we discuss in a dedicated section below.

PH and metal ions

Low pH can be viewed as a factor promoting protein aggregation by increasing the net surface charge and hence enhance side chain repulsion, allowing the exposure of the aggregation-prone hydrophobic core [37]. Indeed, the growth of α-synuclein fibrils was shown to be impaired at neutral pH while it was magnified at mildly acidic pH values (5.8) [38], indicating a critical role of the chemical conditions of the micro-environment surrounding the nascent fibril. Similarly, changes in the environmental pH have been found to affect the amyloidogenic properties of β2-microglobulin, a protein expressed in nucleated plasmatic cells whose aggregates are found in dialysis-related amyloidosis at acidic pH levels [39]. Metal ions have been shown to behave similarly to pH variations by neutralizing charge repulsion and thus imposing a more compact and aggregation-prone structure to α-synuclein [40]. The efficiency in inducing the folding increases with the charge density, reaching a maximum at approximately 2.5 Å− 3. Therefore, small polyvalent cations are more effective in triggering the structural changes when compared to large monovalent cations. Polyvalent cations may also create bridges between carboxylate residues, further increasing the transition to a partially folded structure.


Polyamines are a group of physiological polycations involved in several biological functions, spanning from DNA replication to protein synthesis [41]. They present multivalent cations separated by aliphatic hydrocarbon chains, through which they can interact with natively unfolded proteins both via electrostatic and hydrophobic interactions [42]. High order polyamines, such as putrescine, spermine and spermidine, have been found to be involved in cellular toxicity during the development of PD [43]. Polyamines have been shown to enhance α-synuclein aggregation in a manner proportional to the cation charge and the length of the aliphatic chains separating the amino groups [44]. Therefore, the most potent among them is spermine, which owns four cationic groups separated by three hydrocarbon chains. An in-depth study of the conformational change of α-synuclein induced by spermine has been carried out using force spectroscopy coupled with atomic force microscopy [45]. Here, the C-terminal alanine of α-synuclein has been substituted with a cysteine, thus allowing the covalent binding to the tip of the atomic force microscope and to the mica surface. With this experimental design, researchers were able to show that α-synuclein assembly is potently enhanced by polyamines at the very first steps of the process, indicating that even the first steps of the aggregation (i.e., dimerization) may show heterogeneity.


Proteoglycans are glycoproteins containing sulphated glycosaminoglycan chains (GAG). They are expressed in the outer leaflet of the cellular membrane, where they are involved in the internalization of amyloids [46, 47]. Due to the presence of both a negatively charged moiety (sulphated groups) and a positively charged amino acids, their binding to amyloids has been reported to be both detrimental and protective [48, 49] and, consequently, different types of proteoglycans may display opposite effects towards protein aggregation.

Agrin, a neuronal heparin sulphate proteoglycan, has been found to localize with all Alzheimer’s lesions and has been proposed to contribute to the formation of LBs and neurites. Binding studies and circular dichroism analyses have shown that agrin increases the insolubility of α-synuclein in vitro and enhances the formation of the fibrils [50]. Since agrin contains two potential sites for the attachment of GAG moieties, a subset of glycosylated agrins may exist in the brain, each owing different functions and distinct affinities for α-synuclein.

Nucleic acids

Nucleic acids have been reported in association to amyloid plaques and tangles in protein misfolding diseases. Since they own high binding affinity for amyloids, they have been supposed to act as a scaffold to promote protein aggregation [51]. Due to the net positive surface charge of amyloids, the favoured electrostatic interactions of the peptide chain and phosphate groups of nucleic acids promote the aggregation. This interaction may further increase the local concentration of amyloid proteins, supporting the aggregation through interaction of the exposed hydrophobic domains with neighbour proteins [52, 53].

Nucleic acids have been indeed shown to enhance prion protein, superoxide dismutase-1, amyloid-β and tau aggregation [54]. α-Synuclein has been shown to possess differential binding affinity towards different conformations of nucleic acids. Hegde and co-workers [55] studied the binding of α-synuclein with different topologies of DNA by circular dichroism spectroscopy, intrinsic fluorescence and binding to fluorescent reporter for amyloids such as thioflavin-T (Th-T) and ANS. Single-stranded circular DNA was shown to induce the formation of an α-helix within α-synuclein, inhibiting the aggregation, whereas small oligonucleotides and linear double-stranded DNA caused a partial folding that leans towards the aggregated state. Moreover, GC-rich DNA was shown to induce aggregation in a more efficient way compared to AT-rich DNA.

Poly-ADP ribose (PAR)

Poly-ADP ribose (PAR) is a non-coding polynucleotide produced by the PAR polymerase upon DNA damage [56], mediating a form of necrosis termed parthanathos (from the ancient Greek embodiment of death, Thanathos), which represents a major cell death pathway in neurodegenerative diseases [57]. Outside of triggering cell death through the mitochondrial release of the apoptosis initiating factor [58], PAR was shown to accumulate next to the DNA breakage foci upon external or internal stressful events, where it initiates liquid remixing to achieve intracellular, membrane-less compartmentalization [57]. Such newly formed organelles act as a seed for the assembly of IDPs, which are in turn excluded from damaged areas to allow DNA reparation and promote genome stability. Depletion of PARP by CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9) in neuronal cultures was shown to prevent cell death mediated by α-synuclein pre-formed fibrils (PFFs) and to inhibit their propagation to neighbouring cells [59]. Indeed, α-synuclein PFFs were shown to trigger PARP activation via production of nitric oxide and subsequent DNA damage. In turn, PAR overexpression caused enhanced α-synuclein aggregation through liquid remixing, producing α-synuclein strains that were more compact and hence more toxic. These results were replicated in vivo, showing that whereas intrastriatal injection of α-synuclein PFFs in wild type recipient mice caused increased PAR levels and loss of dopaminergic neurons within 6 months, injection in PARP-1 knockout recipient mice failed to trigger neuronal loss.

Fatty acids

Lipid bilayers have been indicated as a factor that may reduce the activation energy barrier required for proteins to accommodate into the amyloid state [60], by interacting with the positively charged surface of amyloidogenic proteins and thus increase the local concentration and unmask the hydrophobic core of the proteins. Many neurodegenerative related proteins, including α-synuclein [61], have been shown to insert to lipid bilayers [60] and have been suggested to act as anchor for fibrils assembly. Indeed, the interaction with biological membranes may increase the local concentration of the unfolded protein, thus increasing the probability of exposing the hydrophobic core that drives protein aggregation. Perrin and co-workers [62] analyzed the exposure of α-synuclein to different fatty acids. Roughly two thirds of α-synuclein forms a vesicle binding domain, which was proposed to serve a role in synaptic physiology [63]. Upon binding to vesicles, α-synuclein is reshaped into an α-helix containing conformation, which was shown to be resistant to various disruption methods, such as SDS, acidification and boiling. However, not every lipid can trigger α-synuclein aggregation, as the length of the acyl chain is critical for the aggregation. Only short and saturated hydrocarbon chains [64] were shown to be able to induce α-synuclein aggregation, whereas poly-unsaturated fatty acids [65] form stable multimers with α-synuclein. Therefore, it appears that α-synuclein aggregation may either be enhanced or quenched according to the kind of fatty acid it binds to. Lastly, the physical properties of the membrane also affect the aggregation, as it was shown that α-synuclein binding to biological membranes is much stronger when it binds to the fluid state compared to the gel phase [66].

Post-translational modifications (PTMs)

The interaction of α-synuclein with the micro-environment is influenced by the presence of PTMs, which may change the degree and the type of interaction, resulting either in enhancing or quenching the kinetic of aggregation. Indeed, the presence of phosphorylated and ubiquitinated α-synuclein is a hallmark of LBs and neurites [67]. Although the role of PTMs in synucleinopathies is more complex and has been extensively reviewed elsewhere [68, 69], we briefly summarized the most relevant PTMs in the process of α-synuclein aggregation.

Clinical and functional studies [70,71,72] converge on the observation that the dysregulation of glucose metabolism may be an important risk factor for the development of α-synuclein related pathologies. Catabolic processing of glucose generates advanced glycation end-products (AGEs), reducing sugars that may covalently bind to proteins, thus affecting their structure and function. By displaying a comprehensive approach involving yeast models, human stem cells, flies and mice models, and human tissues, Vicente Miranda and co-workers [73] demonstrated by a wide variety of biochemical, biophysical imaging and electrophysiological techniques that glycation of α-synuclein in its amino-terminal moiety by AGEs exploits α-synuclein toxicity and aggregation, impairs motor ability and electrophysiological properties. These effects appear to be mediated by the disruption of the N-terminal binding to lipid membranes, altering the trafficking and hindering the ubiquitination, thus impairing the degradation through the proteasomal pathway.

These evidences suggest that hyperglycemia may contribute to the onset of synucleinopathies, substantiating the role of diabetes as a risk factor for Parkinson’s disease. Moreover, the association of AGEs with α-synuclein aggregation corroborates the association between mutations in genes coding for glyoxalase and deglycase enzymes, such as DJ-1 and recessive forms of Parkinson’s disease.

Among the various phospho-sites involved in α-synuclein aggregation, phosphorylation at residue Ser129 appears to be the most relevant in pathology and, therefore, the most studied [74]. However, data diverges in identifying the role of this PTM in pathology, as it was shown to be both protective and toxic [75] in different systems.

In its physiological state, α-synuclein appears to be constitutively N-terminal acetylated [76] at several lysines residues. The presence of this PTM appears to affect the binding to high curvature vesicles and to vesicles owing low negative charge, whereas the binding to highly negative charged structures appears to be unaffected [77]. Overall, acetylation contributes to maintain the equilibrium between monomeric-, soluble forms and tetrameric-, membrane bound assemblies.

Another physiological PTM of α-synuclein is its C-terminal truncation [78, 79], associated with the lysosomal pathway. Carboxyl-terminal truncated α-synuclein has been estimated to constitute 10–25% of the LBs [79]. Indeed, C-terminal truncation has been associated with an increase in self-assembly properties of α-synuclein [78].

Nitration is another common PTM found in LBs [79]. Nitric oxide is produced upon oxidative stress, causing the nitration of tyrosine residues. Nitration of tyrosine residues in α-synuclein is supposed to hinder the formation of aggregates [80], causing the formation of dityrosine bridges that stabilizes low molecular weight oligomers.

When purified from LBs, α-synuclein appears to be mono-ubiquitinated [81]. The addition of a single ubiquitin molecule is a signal for proteasome degradation, whereas poly-ubiquitination triggers the degradation through the lysosomal pathway [82, 83]. However, α-synuclein may also be conjugated with the small ubiquitin like modifier (SUMO) in a process termed SUMOylation [84]. The addition of this residue was shown to have opposite effect to ubiquitination [85]. Whereas ubiquitination favours the degradation of α-synuclein, SUMOylation was shown to inhibit synuclein ubiquitination, leading to an increase of the local concentration of α-synuclein and therefore promoting the aggregation process.

Lastly, the presence of other proteins may affect the aggregation process. Although homotypic seeding is the preferred form of aggregation, heterotypic cross-seeding of α-synuclein with other natively unfolded proteins (such as tau or PrPC [86, 87]) has been reported as well.

Physical factors that may impact amyloidogenesis are ascribed to thermodynamic events. Temperature, concentration and the application of an external force may increase the entropy of the system, hence increasing the chances of triggering the aggregation.

The sum of biological and physical factors dramatically impacts the experimental detection of the misfolding and aggregation process. Whereas the presence of aggregates has been classically studied by forcing the formation of fibrils in vitro [88, 89], the most recent techniques take advantage of the prion-like mechanism to seed the conversion, and thus reducing the time for the detection of the aggregates. Indeed, the presence of a single misfolded unit enhances dramatically the aggregation by the transmission (in vitro and in vivo) of its conformational information to natively folded neighbour molecules, giving rise to self-propagating molecules. The misfolding and prion-like conversion behaviour of one or more proteins has been observed in a wide variety of neurodegenerative diseases [8, 14, 15, 35]. Currently, the conversion behaviour of misfolded proteins (e.g. α-synuclein) is the basis for the development of a group of methodologies analyzing the process of protein misfolding in vitro.

Protein misfolding cyclic amplification assays

The importance of the self-assembly properties in the onset of neurodegenerative diseases have led to the investigation of the kinetic of the aggregation. During the onset of the pathology, this process is typically slow. However, it can be mimicked in vitro and, under appropriate conditions, it may occur much faster than during pathology. Independently from physical and chemical factors, which may influence the fibrillization process, the presence of a molecule which is prone to aggregation and can act as a nucleus or seed for the fibrillization, allows the reduction of the lag phase and avoids the possible denaturation of the monomers during the reaction [90, 91]. The growth of the α-synuclein fibrils follows a sigmoidal curve (Fig. 1). It displays a lag phase, during which the nucleation process subsequently, the exponential phase indicates the elongation of the fibrils, before a plateau phase can be observed once the monomers have been converted into β-sheet enriched species, which saturates the signal (Fig. 1). The seeded conversion assays have been applied for the detection of misfolded proteins for the diagnosis of prion diseases. In this frame, a fundamental innovation was the development of the protein misfolding cyclic amplification (PMCA) [93]. The aim of the study was to reproduce the conversion of PrP in vitro by seeding the reaction with minute amounts of the misfolded form of PrP. To this end, the aggregation of PrPC from healthy brain homogenates was triggered by the addition of brain homogenates from scrapie-infected hamsters in a cyclic reaction, consisting in cycles of incubation and sonication. The former step allows the seed to contact and convert its native counterpart and to form growing oligomers, whilst the latter step breaks longer fibrils to increase the number of smaller seeding-competent aggregates, hastening the conversion process. The end-product was shown to be proteinase K (PK)-resistant by Western blotting. The PMCA was further automated [94,95,96] to make it suitable for the analyses of biological fluids (blood, urine or the cerebrospinal fluid (CSF) [97, 98]) and, recently, its application was expanded to the detection in biofluids of other neurodegenerative-related molecules, such as the CSF from patients with α-synucleinopathies [99].

Fig. 1

Diagram of the potential seeding-conversion mechanism of α-synuclein during the RT-QuIC. The seed (in red) triggers the aggregation of monomeric α-synuclein (substrate, in green). The conversion causes the conformational modification into misfolded oligomers (blue) that elongate into fibrils. After the detection of fibrils, a quaking event breaks the longer fibrils into shorter, reactive oligomers, which further seed the conversion of monomeric α-synuclein (modified from [92]). The classical shape of the kinetic curve is shown within the aggregation process

To overcome the inherent complications of the PMCA, such as poor reproducibility, the time-consuming need of PK-resistant PrPres detection via Western blotting, the careful handling of the infectious end-product and the lack of consistency with different prion strains [100], other in vitro, cell-free, amplification assays for misfolded proteins have been developed. The substitution of sonication by shaking [101, 102] represented a major advancement. Indeed, by increasing the air-water interface, shaking is thought to cause the unfolding of PrP and to enhance the fragmentation into oligomers, thus favouring the seed-substrate interaction [103]. The assay, termed real-time quaking-induced conversion (RT-QuIC), was further refined by the real-time screening of the course of the reaction by adding the fluorescent dye Th-T (Fig. 1). In this assay, small amounts of misfolded PrPSc seeds recruit single recombinant PrPC substrate molecules and induce their conversion by integrating them into a growing amyloid aggregate concomitant with a conformational change of the substrate into a seeding-competent state (Fig. 1) [92, 101]. The RT-QuIC consists of cycles of incubation steps, where the size of the amyloid product, PrPRes, increases exponentially and vigorous shaking steps, which fragment PrPSc aggregates into smaller seeds promoting the conversion (Fig. 1). The PrPSc-seeded conversion reaction product, PrPRes, is enriched in β-sheet secondary structures. The generation of these β-sheets can be monitored in real-time by using a temperature-controlled shaking fluorescence plate reader and by adding a fluorescence dye, Th-T, in the reaction mix.

Development of the α-synuclein RT-QuIC

In contrast to previous diagnostic assays (colorimetric ELISA, Western blot etc.) for analysis of surrogate biomarker proteins (such as tau and 14–3-3), whose regulation in CSF is based on neurodegeneration process in brain tissue, RT-QuIC analysis allows an ultrasensitive (femtomolar) detection of pathogenic proteins, exhibiting a specificity close to 100% [92]. Recently, the RT-QuIC was successfully applied for the template-induced seeding conversion of α-synuclein, which enables the detection of α-synuclein misfolded species reported by different groups, employing different protocols in regards of the physical conditions (e.g., shaking, temperature, chaotropic agents) and chemical micro-environment (e.g., pH, ionic strength, presence of detergents).

Fairfoul and colleagues detected by RT-QuIC the seeding activity of misfolded α-synuclein derived from both CSF and brain homogenates [104]. The reaction was promoted by the addition of zirconia/silica beads to achieve sensitivity of 95% and specificity of 92–100%, respectively for DLB and PD diagnosis. Further, the authors reported the detection of prodromal stages of DLB, showing positive RT-QuIC results from cases affected by rapid eye movement (REM) behaviour sleep disorder, a hallmark of the prodromal stage of DLB. A biochemical and biophysical characterization of the RT-QuIC products from RT-QuIC reactions seeded with DLB derived brain homogenates was conducted by Sano and co-workers [105]. They obtained an accuracy of 100% specificity, 92% sensitivity for DLB and 95% sensitivity for PD. The tested α-synuclein was either wild-type, phosphorylated at residue 129 (pSer129) (commonly observed in patients with α-synucleinopathies) or non-phosphorylable α-synuclein, containing a point mutation (S129A). The seeding activity of S129A oligomers was higher than that of wild-type oligomers regardless of phosphorylation state. In a second RT-QuIC passage (that is, using the RT-QuIC products as seed for a second run), the highest seeding activity was observed when oligomeric species were produced by S129A α-synuclein in the presence of ATP and casein kinase (CK, that phosphorylates α-synuclein at residue S129), whereas wild-type α-synuclein in presence of either CK alone or both CK and ATP, showed a lower aggregation signal. These results point toward a possible protective effect of pSer129, which may generate inert fibrils faster hindering the aggregation. However, the presence of ATP alone was not investigated, as the presence of the nucleoside may promote the aggregation regardless the primary sequence of the substrate.

Another group, Groveman et al. [106], reported an aggregation of monomeric α-synuclein in reactions seeded with CSF or brain homogenate from DLB and PD patients. 100% of specificity and 93% of sensitivity for α-synucleinopathies (DLB and PD grouped together) was obtained by using as substrate α-synuclein owing a point mutation, K23Q, which confers a lower propensity to self-aggregation.

Manne and co-workers [107] achieved α-synuclein aggregation in the RT-QuIC by using as seed either CSF or brain homogenates in combination of SDS and chaotropic agents (zirconia/silica beads, similarly to Fairfoul’s protocol) to enhance the conversion of monomeric α-synuclein in RT-QuIC reactions, seeded with DLB and PD brain homogenates, with PD CSF and with a subset of progressive supranuclear palsy (PSP, a neurodegenerative disease characterized by tau aggregates). Moreover, researchers induced α-synuclein aggregation in reactions seeded with protein extracts from a microglial cell culture infected with pre-formed α-synuclein fibrils. The observations indicate that the seed for the RT-QuIC can also derive from a cell system.

Candelise and co-workers recently published a study in which positive RT-QuIC signals could be obtained specifically from DLB-brain seeded reactions [108]. In order to avoid possible contamination from macromolecules that may skew the aggregation process, a new pre-analytical fractionation protocol for brain homogenates was established. Under avoidance of bead addition (artificial inducer of α-synuclein aggregation), the α-synuclein RT-QuIC was successfully applied for the specific discrimination of DLB patients (positive response) from PD (negative response on control level). Biochemical analyzes confirmed the generation of a fibrillary, proteinase K (PK)-resistant seeding competent α-synuclein species only in DLB-brain seeded RT-QuIC reactions, pointing toward the existence of different α-synuclein strains in DLB and PD cases. Importantly, the RT-QuIC results were neither influenced by the brain region analyzed nor by the co-pathology or other epidemiological factors, such as age, sex, severity of the disease, and age of onset [108]. Controversial findings regarding a lack of α-synuclein seeding in PD patients might be explained by the addition of beads and the pre-analytical treatment (fractionation protocol) [104, 106]. Further factors, such as the kind of purification method of recombinant α-synuclein substrate or the presence of additional compounds (e.g. SDS, metals) may also have an impact on the seeding response.

The standard purification protocol includes a HPLC/FPLC step [105]. This step is particularly important for removing nucleic acids, as the presence of DNA/RNA influences the aggregation kinetics. Moreover, α-synuclein is prone to bind metal ions, specially copper (e.g. His50) which accelerate its aggregation. Therefore, standard protocols to purify recombinant α-synuclein from E. coli include chelator compounds, commonly EDTA, in the purification buffers. Finally, there are different purified α-synuclein species generated during the purification process (oligomeric and monomeric). Specifically the oligomeric species (removable by an additional filtration step) is prone to aggregation which results in a higher seeding propensity in the RT-QuIC as well as in self-aggregation of the substrate.

Garrido and co-workers [109] applied the protocol originally proposed by Fairfoul [104] and used in other studies [110, 111] to assess the presence of α-synuclein aggregation competent species in the CSF derived from α-synucleinopathies patients carrying a genetic PD mutation in the gene coding for leucine -rich repeat kinase 2 (LRRK2). By testing 10 idiopathic PD cases, they found a specificity of 90% and a specificity of 80%. Samples derived from LRRK-PD subjects showed a specificity of 40% (6 out of 15), while 3 of 16 (18.8%) of non-manifesting LRRK2 carriers showed a positive RT-QuIC signal response.

Finally, De Luca et al [112] performed a cross-sectional observational study, carried out by seeding the RT-QuIC reaction with brain material derived from cases affected by PSP, frontotemporal dementia (FTD) and corticobasal degeneration (CBD), PD and MSA. Serial steps of high speed centrifugation were conducted to enrich the seeding-competent α-synuclein species and diluted to a working concentration of 10− 3. Moreover, they obtained 47 samples of olfactory mucosa (OM) from PD, MSA, PSP and CBD cases. Researchers were able to detect seeding activity from reactions seeded with brain homogenates from PD and MSA patients, while no signal could be detected from reactions seeded with PSP, CBD, FTD or controls. When testing the OM samples, they detected seeding activity in 10 out of 18 PD cases (55.5% sensitivity) and in 9 out of 11 MSA cases (81.8% sensitivity). Thus, the overall sensitivity of PD and MSA grouped cases was 65.5%, whereas negative controls from PSP and CBD gave positive results respectively in 1 out of 6 and 2 out of 12 cases (overall specificity 84.3%). Both brain -and OM seeded reactions showed a lag phase of approximately 40 h. The group further analyzed the RT-QuIC fibrils by transmission electron microscopy, considering the length, the shape and the number of fibrils in the RT-QuIC end-products seeded with OM derived material. They found a statistically significant difference between PD derived fibrils and MSA derived fibrils, with the former owing a shorter over-twist distance compared to the latter. These fibrils were different from those derived from the positive RT-QuIC assays seeded with PSP and CBD material (respectively, PSP derived were longer than MSA, whilst CBD were the shortest produced during the RT-QuIC).

Thus, outside of the great improvement in the usage of a seed derived from a source other than CSF (which dramatically improves the well-being of a patient, compared to the painful procedure of the lumbar puncture), they also produced evidences of a difference in the seeding activity of PD derived α-synuclein compared to MSA derived α-synuclein, indicating a putative strain difference between both pathologies, in line with previous studies reporting putative strain differences among synucleinopathies [113,114,115].

Even though several studies (mentioned before) observed a seeding activity of pathogenic α-synuclein, their protocols were different for chemical and physical conditions and, more importantly, for the starting seed and the kind of purified α-synuclein substrate used for the reactions. Most of the groups used human full length α-synuclein from different companies, and different kinds of beads were added in the reaction to accelerate the conversion. In addition, the purified α-synuclein substrate can already be partially aggregated (preformed fibrils) or genetic (PD mutations were included in the substrate sequence), enhancing the seeding propensity in the RT-QuIC reaction. The presence of the positively charged histidine moiety (required for the purification), may further promote the self-aggregation properties of α-synuclein. Moreover, the addition of further compounds such as SDS can change the seeding kinetic and the sensitivity of the α-synuclein RT-QuIC. Differences among protocols and their clinical accuracy (specificity, sensitivity) are summarized in table form (Table 2).

Table 2 Comparison of different α-synuclein RT-QuIC protocols. The table summarizes the differences in the protocols so far developed to detect α-synuclein seeding activity in the RT-QuIC. In Fairfoul et al., * 42 DLB samples included 12 pure DLB, 17 DLB + AD and 13 AD with incidental Lewy bodies. ** Not determined. *** In Kang et al., T50 (time to reach 50% of the maximum of fluorescence) was calculated as function of the unified Parkinson disease rating scale (UPDRS) instead of the lag time. T50 was approximately 50 h. **** Due to the limited number of samples analysed, De Luca et al. decided both to calculate specificity and sensitivity. Extracting these data from the paper resulted in specificity of 65.5% and sensitivity 84.3% for OM seeded reactions

It is therefore apparent that multiple experimental settings may be exploited for the detection of α-synuclein seeding activity in the RT-QuIC. A different “micro-environment” in the reactions, different physical conditions for the aggregation, a different source for the seed, the usage of different substrates or more probably the combinations of these factors, may lead to the detection of α-synuclein seeding activity from different α-synucleinopathies.

Upon protein aggregation, a population of conformational variants could be produced, which compete for the same source (i.e., the native version of the misfolded protein) as a function of the environmental conditions. The different conformations that arise from the same misfolded protein have been referred as strains.

Evidences for the existence of different α-synuclein strains

The term “strain” was first introduced to discriminate the pathological phenotypes associated with the intracerebral inoculation of the prion protein in goats [116,117,118]. Upon misfolding, a single unit may accommodate into different conformations, giving rise to different pathological frames. Strains hence refer to separate conformations of the same protein. Since their inception in the prion field, a variety of strains has been characterized [119, 120]. The conformation may be altered by the genetic background of the host and the source of the pathogenic protein, as well as post-translational modifications, chemical and physical conditions of the micro-environment in which the process takes place, leading to a heterogeneous strain population.

Different transmission properties of α-synuclein species in vitro and in vivo

The transmissibility of misfolded α-synuclein (either from brain homogenates of a donor or recombinantly produced fibrils) indicates a prion-like seeding and conversion activity. Relevant for a successful transmission of α-synuclein fibrils in rodent brains inducing a Parkinson-like pathology is an overexpression of α-synuclein which serves as a substrate for the inoculated α-synuclein seed [121].

The transmissibility of MSA derived α-synuclein was demonstrated by the injection of brain homogenates from MSA patients into hemizygous TgM83+/− mice [111], which possess the mutation A53T, associated with familial forms of PD [122].

TgM83+/− rapidly developed signs of synucleinopathy and widespread deposition of LBs upon intracerebral inoculation of brain extracts from MSA cases. However, fibrils extracted from TgM83+/+ (homozygous for the mutation, naturally developing α-synuclein aggregates) were not able to passage the pathology when injected in TgM83+/− mice. The same group reported in a follow up study [123] that fibrils derived from brain homogenates derived from PD patients were not able to trigger the pathology when injected into hemizygous mice or in HEK cells owing the same A53T mutation, similarly to what could be observed with fibrils derived from TgM83+/+ mice. These results indicated that different strains of α-synuclein underlie the clinical manifestations of PD and MSA.

Moreover, brain homogenates derived from DLB and MSA patients also differed in their seeding activity when injected into wild-type mice [113]. In addition, MSA derived α-synuclein is more aggressive than PD/DLB, which may depend on the conformation of the misfolded seed (more compact structure) as well as from the intracellular environment [115]. MSA- and PD/DLB α-synuclein have no cell type preference in seeding α-synuclein pathology, even though they showed a different cell type distribution in MSA and DLB. In transmission studies (carried out in TgM83+/− mice that were hemizygous for the human α-synuclein A53T transgene) with MSA α-synuclein there is a predominance of neuronal over oligodendroglial inclusions, which might be a consequence of the “artificial environment” not reflecting the conditions in MSA patients. In this context it was reported that the cellular milieu in oligodendrocytes is responsible for the transformation of misfolded α-synuclein into a MSA strain [115], while seeding activity of MSA-α-synuclein is maintained when propagated in neurons, which shows that the strain characteristics depend also on the conformation of the misfolded seed [115].

The first evidence of the ability of α-synuclein aggregates to produce different strains was performed by incubating monomeric α-synuclein in different salt concentrations [124].

High salt (termed buffer A) resulted in the formation of assemblies within hours, whereas low salt buffer (buffer B) had a longer lag phase before aggregation. Aggregate formation from buffer A was reversible (they depolymerize by incubation at 4 °C and re-polymerize upon heating at 37 °C). In contrast, aggregates formed in buffer B were irreversible.

Electron microscope analysis revealed differences in the structure of these aggregates. Assemblies from buffer A showed a cylindrical aspect, while aggregates derived from buffer B had a planar and often twisted structure. Due to their appearances, buffer A aggregates were termed fibrils and buffer B assemblies were termed ribbons. These two species were shown to further differ for their PK banding profile. Different PK profiles are generated due to different cleavage sites of the PK, which may depend on the conformation of misfolded α-synuclein. Indeed, ribbons could not bind to Th-T, whereas fibrils did. The structure of these aggregates also differs, with ribbons owing a rigid and β-sheet enriched N-terminal moiety, whereas the N-terminal part of the fibrils appears to be mostly disordered [124]. The two strains were further distinguished by their toxicity upon administration into human neuroblastoma SH-SY5Y cell cultures, with ribbons causing a less extensive cell deaths compared to fibrils. In a following study [114], fibrils and ribbons were reported to bear pathogenic potential when injected in the substantia nigra of rats, with fibrils exhibiting the highest toxic effect compared to oligomers or ribbons, indicating that strains can be further differentiated by their cytotoxic effects. Lastly, serial sonication steps were reported to produce a synthetic α-synuclein strain which displays less ability in seeding the aggregation of α-synuclein in neuronal cultures compared to PFFs. However, this strain had a greater ability of seeding tau aggregation in vitro [86] but only a minor effect on tau aggregation in transgenic mice. The presence of lipopolysaccharides was further reported to produce different conformations of α-synuclein fibrils [125].

Although α-synuclein oligomers are considered as the main reactive species for the onset of neurodegeneration [21], there are evidences of stabilized protofibrils that are unable to form mature fibrils. These species are termed off-pathway oligomers, as they result in stable oligomers lacking in seeding activity [126]. Various types of off-pathway oligomers have been generated in vitro by the addition of molecules that allow the formation of kinetically stable molecules unable to further aggregate into fibrils. Several molecules have been shown to favour the formation of off-pathway oligomers. By varying the salt-, buffer- and pH environmental conditions, Pham and co-workers [127] showed that different dopamine redox products display various effects on in vitro α-synuclein aggregation. Specifically, whereas under acidic conditions dopamine is stable and inhibits the oligomerization, higher pH values cause the formation of redox catabolites of dopamine, which promote the formation of soluble, SDS-resistant, off-pathway oligomers. However, the same redox product, 5,6-dihydroxyindole, induces the formation of on-pathway oligomers under acidic conditions generating fibrils that are Th-T insensitive.

Peroxidation-derived reactive aldehydes, such as 4-oxo-2-nonenal (ONE), have been shown to produce off-pathway oligomers as well [128]. However, these α-synuclein oligomers exhibit a beta-sheet structure and appear to be able to induce the formation of fibrils with a reduced rate of fibrillation.

Lastly, α-synuclein off-pathway oligomers may be generated by the presence of the polyphenol epigallocatechin gallate (EGCG [129]), a potent inhibitor of the in vitro aggregation of huntingtin and α-synuclein.

The scheme for the aggregation pathway of natively unfolded proteins (Fig. 2A) may therefore be implemented (as shown in Fig. 2B) by taking into account the environmental factors and the production of a population of strains, whose constraints are dependent on the minimization of the free energy of the conformer and ultimately converge into a limited variety of fibrillary structures or off-pathway species (Fig. 2B) (in case of α-synuclein, fibrils, ribbons and amorphous aggregates [19, 40]).

Figure 2

Proposed models for the aggregation pathway. a Established schematic view for the pathway of aggregation of natively unfolded proteins [40]. According to this model, from an unfolded protein (UN) is formed an intermediate (I), which further aggregates into protofibrils (P) and eventually into fibrils (F). b The extended model we propose takes into account the possibility that a population of strains are produced, together with off-pathway oligomers that do not show the ability to form α-synuclein fibrils. Intermediate forms marked as I1 to In, each of them may produce a different protofibrillar form, marked as P1-n to Pn-n (the protofibril P1 derived from the intermediate I1 until the protofibril Pn derived from the intermediate In). It is noteworthy to state that the process may be in equilibrium between the aggregation of the intermediates and the rupture of protofibrillar forms. Further aggregation will cause the collapse into a limited number of fibrillar structures


Since the introduction of the concept of self-propagating proteins as common feature in neurodegenerative diseases, whether different conformations, or strains of pathogenic proteinaceous material might underlie similar diseases has been a long lasting conundrum. As strains may emerge from light variations in the reaction micro-environment and from the binding to different partners, an in-depth characterization of both the reaction conditions and the presence of biomolecules appear to be necessary. Here we extend the classical view of protein aggregation to include strain variability and micro-environmental factors that may aid to understand the heterogeneity of conformational variants of a natively unfolded protein such as α-synuclein.

“Pure” α-synucleinopathies strikingly differ for their clinical manifestation, route of spreading and prodromic phase of the disease. As the technology of in vitro, cell-free systems, such as the RT-QuIC, progresses, subtle differences of the misfolded species of proteins that may contribute to neurodegenerative diseases are starting to manifest, indicating that strain-typing might be a relevant factor behind the clinical course of similar, albeit different diseases, as in the case of PD and DLB.

Here, we attempted to comprehensively review the complex landscape that regulates the folding and aggregation of α-synuclein, scouring through the intrinsic (i.e., mutations associated with pathology and PTMs) and extrinsic (micro-environmental) factors that influence the topology of α-synuclein both in pathology and physiology. These factors need to be taken into account in order to develop reliable assays for the diagnosis of α-synucleinopathies.

Indeed, to establish the α-synuclein RT-QuIC in the diagnostic of α-synucleinopathies (pre-mortem in CSF or post-mortem in brain) the following standardization steps will be required: 1) Pre-analytical sample treatments (type of storage tube), 2) harmonization of test-protocols (composition of the reaction mix, kind of α-synuclein substrate, incubation times and shaking etc.), 3) definition of a positive reaction, 4) determination of stability of the misfolded α-synuclein seed against storage conditions, and 5) investigation of the tolerance of the RT-QuIC against blood contamination.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.



Dementia with lewy body


Frontal cortex


Glycosaminoglycan chains


Intrinsically disordered proteins

Lewy body dementia; LBs:

Lewy bodies


Multiple system atrophy


Parkinson’s disease


Pre-formed fibril


Proteinase K

PrPC :

Cellular prion protein

PrPSc :

Scrapie prion protein


Posttranslationale modifications


Rapid eye movement


Relative fluorescence units


Real-time quaking-induced conversion


Substantia nigra pars compacta




  1. 1.

    Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol. 2011;122:187–204.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  2. 2.

    Schönfelder J, Alonso-Caballero A, De Sancho D, Perez-Jimenez R. The life of proteins under mechanical force. Chem Soc Rev. 2018;47(10):3558–73.

    PubMed  Article  PubMed Central  Google Scholar 

  3. 3.

    Balchin D, Hayer-Hartl M, Hartl FU. In vivo aspects of protein folding and quality control. Science. 2016;353(6294):acc4354.

    Article  CAS  Google Scholar 

  4. 4.

    Eisenberg D, Jucker M. The amyloid state of proteins in human diseases. Cell. 2012;148(6):1188–203.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Oldfield CJ, Dunkler AK. Intrinsically disordered proteins and intrinsically disordered protein regions. Ann Rev Biochem. 2014;83:553-84.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  6. 6.

    Carrell RW, Gooptu B. Conformational changes and disease—Serpins, prions and Alzheimer’s. Curr Opin Struct Biol. 1998;8(6):799–809.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  7. 7.

    Frantzmann T, Alberti S. Prion-like low-complexity sequences: key regulators of protein solubility and phase behavior. J Biol Chem. 2018;294(18):7128-36.

  8. 8.

    Dobson CM. Protein misfolding, evolution and disease. Trends Biochem Sci. 1999;24(9):329–32.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  9. 9.

    Skrabana R, Sevcik J, Novak M. Intrinsically disordered proteins in the neurodegenerative processes: formation of tau protein paired helical filaments and their analysis. Cell Mol Neurobiol. 2006;26(7–8):1085–97.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Uversky VN, Oldfield CJ, Midic U, Xie H, Xue B, Vucetic S, Iakoucheva LM, Obradovic Z, Dunker AK. Unfoldomics of human diseases: linking protein intrinsic disorder with diseases. BMC Genomics. 2006;10 Suppl 1:S7.

    Google Scholar 

  11. 11.

    Levine ZA, Larini L, LaPointe NE, Feinstein SC, Shea JE. Regulation and aggregation of intrinsically disordered peptides. Proc Natl Acad Sci U S A. 2015;112(9):2758–63.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  12. 12.

    Kirschner DA, Abraham C, Selkoe DJ. X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation. Proc Natl Acad Sci U S A. 1986;83(2):503–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    Kisilevsky R, Raimondi S, Bellotti V. Historical and current concepts of Fibrillogenesis and in vivo Amyloidogenesis: implications of amyloid tissue targeting. Front Mol Biosci. 2016;3:17.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  14. 14.

    Soto C. Protein misfolding and disease; protein refolding and therapy. FEBS Lett. 2001;498(2–3):204–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  15. 15.

    Soto C. Unfolding protein misfolding in neurodegenerative diseases. Nat Rev Neurosci. 2003;4(1):49–60.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  16. 16.

    Prusiner SB. Prions: novel infectious pathogens. Adv Virus Res. 1984;29:1–56.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  17. 17.

    Prusiner SB. Biology and genetics of prion diseases. Annu Rev Microbiol. 1994;48:655–86.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  18. 18.

    Goedert M, Jakes R, Spillantini MG. The Synucleinopathies: twenty years on. J Park Dis. 2017;7(s1):S51–69.

    Google Scholar 

  19. 19.

    Peelaerts W, Baekelandt V. ɑ-Synuclein strains and the variable pathologies of synucleinopathies. J Neurochem. 2016;139(Suppl. 1):256–74.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  20. 20.

    Roostaee A, Beaudoin S, Staskevicius A, Roucou X. Aggregation and neurotoxicity of recombinant α-synuclein aggregates initiated by dimerization. Mol Neurodegener. 2013;8:5.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  21. 21.

    Bengoa-Vergniory N, Roberts RF, Wade-Martins R, Alegre-Abarrategui J. Alpha-synuclein oligomers: a new hope. Acta Neuropathol. 2017;134(6):819–38.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Serio TR, Cashikar AG, Kowal AS, Sawicki GJ, Moslehi JJ, Serpell L, Arnsdorf MF, Lindquist SL. Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science. 2000;289(5483):317–1321.

    Article  Google Scholar 

  23. 23.

    Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008;14(5):504–6.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  24. 24.

    Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord. 2008;23(16):2303–6.

    PubMed  Article  PubMed Central  Google Scholar 

  25. 25.

    Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Björklund A, Widner H, Revesz T, Lindvall O, Brundin P. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med. 2008;14(5):501–3.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  26. 26.

    Alvarez-Erviti L, Seow Y, Schapira AH, Gardiner C, Sargent IL, Wood MJ, Cooper JM. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis. 2011;42(3):360–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  27. 27.

    Sung JY, Kim J, Paik SR, Park JH, Ahn YS, Chung KC. Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein. J Biol Chem. 2001;276(29):27441–8.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  28. 28.

    Eichmann C, Kumari P, Riek R. High-density lipoprotein-like particle formation of Synuclein variants. FEBS Lett. 2017;591(2):304–11.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  29. 29.

    Lööv C, Scherzer CR, Hyman BT, Breakefield XO, Ingelsson M. α-Synuclein in extracellular vesicles: functional implications and diagnostic opportunities. Cell Mol Neurobiol. 2016;36(3):437–8.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  30. 30.

    Ngolab J, Trinh I, Rockenstein E, Mante M, Florio J, Trejo M, Masliah D, Adame A, Masliah E, Rissman RA. Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology. Acta Neuropathol Commun. 2017;5(1):46.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  31. 31.

    Luk KC, Covell DJ, Kehm VM, Zhang B, Song IY, Byrne MD, Pitkin RM, Decker SC, Trojanowski JQ, Lee VM. Molecular and biological compatibility with host alpha-synuclein influences fibril pathogenicity. Cell Rep. 2016;16(12):3373–87.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Freundt EC, Maynard N, Clancy EK, Roy S, Bousset L, Sourigues Y, Covert M, Melki R, Kirkegaard K, Brahic M. Neuron-to-neuron transmission of α-synuclein fibrils through axonal transport. Ann Neurol. 2012;72(4):517–24.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Rey NL, Steiner JA, Maroof N, Luk KC, Madaj Z, Trojanowski JQ, Lee VM, Brundin P. Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. J Exp Med. 2016;213(9):1759–78.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  34. 34.

    Ulusoy A, Rusconi R, Pérez-Revuelta BI, Musgrove RE, Helwig M, Winzen-Reichert B, Di Monte DA. Caudo-rostral brain spreading of α-synuclein through vagal connections. EMBO Mol Med. 2013;5(7):1119–27.

    PubMed  Article  CAS  Google Scholar 

  35. 35.

    Naiki H, Nagai H. Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteins. J Biochem. 2009;146(6):751–6.

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    Coskuner O, Wise-Scira O. Structures and free energy landscapes of the A53T mutant-type α-synuclein protein and impact of A53T mutation on the structures of the wild-type α-synuclein protein with dynamics. ACS Chem Neurosci. 2013;4(7):1101–13.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  37. 37.

    Buell AK, Galvagnion C, Gaspar R, Sparr E, Vendruscolo M, Knowles TP, Linse S, Dobson CM. Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation. Proc Natl Acad Sci U S A. 2014;111(21):7671–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  38. 38.

    Grey M, Linse S, Nilsson H, Brundin P, Sparr E. Membrane interaction of alpha-synuclein in different aggregation states. J Park Dis. 2011;1(4):359–71.

    CAS  Google Scholar 

  39. 39.

    Naiki H, Yamamoto S, Hasegawa K, Yamaguchi I, Goto Y, Gejyo F. Molecular interactions in the formation and deposition of beta2-microglobulin-related amyloid fibrils; 2005.

    Google Scholar 

  40. 40.

    Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem. 2001;276(47):44284–96.

    CAS  PubMed  Article  Google Scholar 

  41. 41.

    Pegg AE, McCann PP. Polyamine metabolism and function. Am J Phys. 1982;243(5):C212–21.

    CAS  Article  Google Scholar 

  42. 42.

    Antony T, Hoyer W, Cherny D, Heim G, Jovin TM, Subramaniam V. Cellular spermidine promote the aggregation of alpha-synuclein. J Biol Chem. 2003;278(5):3235–40.

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    Lewandowski NM, Ju S, Verbitsky M, Ross B, Geddie ML, Rockenstein E, Adame A, Muhammad A, Vonsattel JP, Ringe D, Cote L, Lindquist S, Masliah E, Petsko GA, Marder K, Clark LN, Small SA. Polyamine pathway contributes to the pathogenesis of Parkinson disease. Proc Natl Acad Sci U S A. 2010;107(39):16970–5.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  44. 44.

    Krasnoslobodtsev AV, Peng J, Asiago JM, Hindupur J, Rochet JC, Lyubchenko YL. Effect of spermidine on misfolding and interactions of alpha-synuclein. PLoS One. 2012;7(5):e38099.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO, Brodsky FM, Marasa J, Bagchi DP, Kotzbauer PT, Miller TM, Papy-Garcia D, Diamond MI. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A. 2013;110(33):E3138–47.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    Ihse E, Yamakado H, van Wijk XM, Lawrence R, Esko JD, Masliah E. Cellular internalization of alpha-synuclein aggregates by cell surface heparan sulfate depends on aggregate conformation and cell type. Sci Rep. 2017;7(1):9008.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  47. 47.

    Cohlberg JA, Li J, Uversky VN, Fink AL. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry. 2002;41(5):1502–11.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  48. 48.

    Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2013;14(1):38–48.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  49. 49.

    Perry G, Richey P, Siedlak SL, Galloway P, Kawai M, Cras P. Basic fibroblast growth factor binds to filamentous inclusions of neurodegenerative diseases. Brain Res. 1992;579(2):350–2.

    CAS  PubMed  Article  Google Scholar 

  50. 50.

    Liu IH, Uversky VN, Munishkina LA, Fink AL, Halfter W, Cole GJ. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation. Glycobiology. 2005;15(12):1320–31.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  51. 51.

    Liu C, Zhang Y. Nucleic acid-mediated protein aggregation and assembly. Acta Protein ChemStruct Biol. 2011;84:1–40.

    CAS  Google Scholar 

  52. 52.

    Cordeiro Y, Silva JL. The hypothesis of the catalytic action of nuclei acid on the conversion of prion protein. Protein Pept Lett. 2005;12:251–5.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  53. 53.

    Yin J, Chen R, Liu C. Nucleic acid induced protein aggregation and its role in biology and pathology. Front Biosci (Landmark Ed). 2009;14:5084–106.

    CAS  Article  Google Scholar 

  54. 54.

    Cordeiro Y, Macedo B, Silva JL, Gomes MPB. Pathological implications of nucleic acid interactions with proteins associated with neurodegenerative diseases. Biophys Rev. 2014;6(1):97–110.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  55. 55.

    Hegde ML, Rao KS. DNA induces folding in alpha-synuclein: understanding the mechanism using chaperone property of osmolytes. Arch Biochem Biophys. 2007;464(1):57–69.

    CAS  PubMed  Article  Google Scholar 

  56. 56.

    Fricker M, Tolkovsky AM, Borutaite V, Coleman M, Brown GC. Neuronal Cell Death. Physiol Rev. 2018;98(2):813–80.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  57. 57.

    Liu C, Fang Y. New insights of poly (ADP-ribosylation) in neurodegenerative diseases: a focus on protein phase separation and pathologic aggregation. Biochem Pharmacol. 2019.

    CAS  PubMed  Article  Google Scholar 

  58. 58.

    Donyo M, Ashkenazi A. The cell-death-associated polymer PAR feeds forward α-synuclein toxicity in Parkinson's disease. Mol Cell. 2019;73(1):5–6.

    CAS  PubMed  Article  Google Scholar 

  59. 59.

    Kam TI, Mao X, Park H, Chou SC, Karuppagounder SS, Umanah GE, Yun SP, Brahmachari S, Panicker N, Chen R, Andrabi SA, Qi C, Poirier GG, Pletnikova O, Troncoso JC, Bekris LM, Leverenz JB, Pantelyat A, Ko HS, Rosenthal LS, Dawson TM, Dawson VL. Poly (ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's disease. Science. 2018;362(6414).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  60. 60.

    Gorobenko GP, Kinnunen KJ. The role of lipid-protein interactions in amyloid-type protein fibril formation. Chem Phys Lipids. 2006;141(1–2):72–82.

    Article  CAS  Google Scholar 

  61. 61.

    Uverski LN, Lee HJ, Li J, Fink AL, Lee SJ. Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J Biol Chem. 2001;276(47):43495–8.

    Article  Google Scholar 

  62. 62.

    Perrin RJ, Woods WS, Clayton DF, George JM. Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J Biol Chem. 2001;276(45):41958–62.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  63. 63.

    Perrin RJ, Woods WS, Clayton DF, George JM. Interaction of human alpha-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J Biol Chem. 2000;275(44):34393–8.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  64. 64.

    Brummel BE, Braun AR, Sachs JN. Polyunsaturated chains in asymmetric lipids disorder raft mixtures and preferentially associate with α-synuclein. Biochim Biophys Acta Biomembr. 2017;1859(4):529–36.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  65. 65.

    Fecchio C, Palazzi L, de Laureto PP. α-Synuclein and polyunsaturated fatty acids: molecular basis of the interaction and implication in neurodegeneration. Molecules. 2018;23(7).

    PubMed Central  Article  CAS  Google Scholar 

  66. 66.

    Galvagnion C, Brown JW, Ouberai MM, Flagmeier P, Vendruscolo M, Buell AK, Sparr E, Dobson CM. Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of α-synuclein. Proc Natl Acad Sci U S A. 2016;13(26):7065–70.

    Article  CAS  Google Scholar 

  67. 67.

    Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee VM, Trojanowski JQ, Mann D, Iwatsubo T. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. Biol Chem. 2002;277(50):49071–6.

    CAS  Article  Google Scholar 

  68. 68.

    Colom-Cadena M, Pegueroles J, Herrmann AG, Henstridge CM, Muñoz L, Querol-Vilaseca M, Martín-Paniello CS, Luque-Cabecerans J, Clarimon J, Belbin O, Núñez-Llaves R, Blesa R, Smith C, McKenzie CA, Frosch MP, Roe A, Fortea J, Andilla J, Loza-Alvarez P, Gelpi E, Hyman BT, Spires-Jones TL, Lleó A. Synaptic phosphorylated α-synuclein in dementia with Lewy bodies. Brain. 2017;140(12):3204–14.

    PubMed  PubMed Central  Article  Google Scholar 

  69. 69.

    Schmid AW, Fauvet B, Moniatte M, Lashuel HA. Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol Cell Proteomics. 2013;12(12):3543–58.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  70. 70.

    Dalfó E, Portero-Otín M, Ayala V, Martínez A, Pamplona R, Ferrer I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol. 2005;64(9):816–30.

    PubMed  Article  PubMed Central  Google Scholar 

  71. 71.

    Gomez A, Ferrer I. Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment. Acta Neuropathol. 2010;120(2):155–67.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  72. 72.

    Shaikh S, Nicholson LF. Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation. J Neurosci Res. 2008;86(9):2071–82.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  73. 73.

    Vicente Miranda H, Cássio R, Correia-Guedes L, Gomes MA, Chegão A, Miranda E, Soares T, Coelho M, Rosa MM, Ferreira JJ, Outeiro TF. Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson's disease. Sci Rep. 2017;7(1):13713.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  74. 74.

    Sato H, Kato T, Arawaka S. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models. Rev Neurosci. 2013;24(2):115–23.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  75. 75.

    Arawaka S, Sato H, Sasaki A, Koyama S, Kato T. Mechanisms underlying extensive Ser129-phosphorylation in α-synuclein aggregates. Acta Neuropathol Commun. 2017;5(1):48.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  76. 76.

    Hwang CS, Shemorry A, Varshavsky A. N-terminal acetylation of cellular proteins creates specific degradation signals. Science. 2010;327:973–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  77. 77.

    Dikiy I, Eliezer D. N-terminal acetylation stabilizes N-terminal Helicity in lipid- and micelle-bound α-Synuclein and increases its affinity for physiological membranes. J Biol Chem. 2014;289(6):3652–5.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  78. 78.

    Sorrentino ZA, Vijayaraghavan N, Gorion KM, Riffe CJ, Strang KH, Caldwell J, Giasson BI. Physiological C-terminal truncation of α-synuclein potentiates the prion-like formation of pathological inclusions. J Biol Chem. 2018;293(49):18914–32.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  79. 79.

    Li W, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L, Dawson TM, Jäkälä P, Hartmann T, Price DL, Lee MK. Aggregation promoting C-terminal truncation of α-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A. 2005;102:2162–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  80. 80.

    Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 2000;290(5493):985–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  81. 81.

    Burai R, Ait-Bouziad N, Chiki A, Lashuel HA. Elucidating the role of site-specific nitration of α-synuclein in the pathogenesis of Parkinson's disease via protein semisynthesis and mutagenesis. J Am Chem Soc. 2015;137(15):5041–52.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  82. 82.

    Engelender S. Ubiquitination of alpha-synuclein and autophagy in Parkinson's disease. Autophagy. 2008;4(3):372–4.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  83. 83.

    Ahmed I, Liang Y, Schools S, Dawson VL, Dawson TM, Savitt JM. Development and characterization of a new Parkinson's disease model resulting from impaired autophagy. J Neurosci. 2012;32(46):16503–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  84. 84.

    Rott R, Szargel R, Shani V, Hamza H, Savyon M, Abd Elghani F, Bandopadhyay R, Engelender S. SUMOylation and ubiquitination reciprocally regulate α-synuclein degradation and pathological aggregation. Proc Natl Acad Sci U S A. 2017;144(50):13176–81.

    Article  CAS  Google Scholar 

  85. 85.

    Krumova P, Meulmeester E, Garrido M, Tirard M, Hsiao HH, Bossis G, Urlaub H, Zweckstetter M, Kügler S, Melchior F, Bähr M, Weishaupt JH. Sumoylation inhibits alpha-synuclein aggregation and toxicity. J Cell Biol. 2011;194(1):49–60.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  86. 86.

    Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong LK, Xu Y, Trojanowski JQ, Lee VM. Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell. 2013;154(1):103–17.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  87. 87.

    Katorcha E, Makarava N, Lee YJ, Lindberg I, Monteiro MJ, Kovacs GG, Baskakov IV. Cross-seeding of prions by aggregated α-synuclein leads to transmissible spongiform encephalopathy. PLoS Pathog. 2017;13(8):e1006563.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  88. 88.

    Polinski NK, Volpicelli-Daley LA, Sortwell CE, Luk KC, Cremades N, Gottler LM, Froula J, Duffy MF, Lee VMY, Martinez TN, Dave KD. Best practices for generating and using alpha-synuclein pre-formed fibrils to model Parkinson's disease in rodents. J Park Dis. 2018;8(2):303–22.

    Google Scholar 

  89. 89.

    Luna E, Decker SC, Riddle DM, Caputo A, Zhang B, Cole T, Caswell C, Xie SX, Lee VMY, Luk KC. Differential α-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity. Acta Neuropathol. 2018;135(6):855–75.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  90. 90.

    Villar-Piqué A, Schmitz M, Candelise N, Ventura S, Llorens F, Zerr I. Molecular and clinical aspects of protein aggregation assays in neurodegenerative diseases. Mol Neurobiol. 2018;55(9):7588–605.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  91. 91.

    Come JH, Fraser PE, Lansbury PT Jr. A kinetic model for amyloid formation in the prion diseases: importance of seeding. Proc Natl Acad Sci U S A. 1993;90(13):5959–63.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  92. 92.

    Schmitz M, Cramm M, Llorens F, Müller-Cramm D, Collins S, Atarashi R, Satoh K, Orrú CD, Groveman BR, Zafar S, Schulz-Schaeffer WJ, Caughey B, Zerr I. The real-time quaking-induced conversion assay for detection of human prion disease and study of other protein misfolding diseases. Nat Protoc. 2016;11(11):2233–42.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  93. 93.

    Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature. 2001;411(6839):810–3.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  94. 94.

    Castilla J, Saá P, Hetz C, Soto C. In vitro generation of infectious scrapie prions. Cell. 2005;12(2):195–206.

    Article  CAS  Google Scholar 

  95. 95.

    Saá P, Castilla J, Soto C. Ultra-efficient replication of infectious prions by automated protein misfolding cyclic amplification. J Biol Chem. 2006;281(46):35245–52.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  96. 96.

    Morales R, Duran-Aniotz C, Diaz-Espinoza R, Camacho MV, Soto C. Protein misfolding cyclic amplification of infectious prions. Nat Protoc. 2012;7(7):1397–409.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  97. 97.

    Castilla J, Saá P, Soto C. Detection of prions in blood. Nat Med. 2005;11(9):982–5.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  98. 98.

    Murayama Y, Yoshioka M, Okada H, Takata M, Yokoyama T, Mohri S. Urinary excretion and blood level of prions in scrapie-infected hamsters. J Gen Virol. 2007;88(pt. 10):2890–8.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  99. 99.

    Shahnawaz M, Tokuda T, Waragai M, Mendez N, Ishii R, Trenkwalder C, Mollenhauer B, Soto C. Development of a biochemical diagnosis of Parkinson disease by detection of α-Synuclein Misfolded aggregates in cerebrospinal fluid. JAMA Neurol. 2017;74(2):163–72.

    PubMed  Article  PubMed Central  Google Scholar 

  100. 100.

    Colby DW, Zhang Q, Wang S, Groth D, Legname G, Riesner D, Prusiner SB. Prion detection by an amyloid seeding assay. Proc Natl Acad Sci U S A. 2007;104(52):20914–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  101. 101.

    Atarashi R, Wilham JM, Christensen L, Hughson AG, Moore RA, Johnson LM, Onwubiko HA, Priola SA, Caughey B. Simplified ultrasensitive prion detection by recombinant PrP conversion with shaking. Nat Methods. 2008;5(3):211–2.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  102. 102.

    Orrú CD, Wilham JM, Hughson AG, Raymond LD, McNally KL, Bossers A, Ligios C, Caughey B. Human variant Creutzfeldt-Jakob disease and sheep scrapie PrP (res) detection using seeded conversion of recombinant prion protein. Protein Eng Des Sel. 2009;22(8):515–21.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  103. 103.

    Collins SR, Douglass A, Vale RD, Weissman JS. Mechanism of prion propagation: amyloid growth occurs by monomer addition. PLoS Biol. 2004;2(10):e321.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  104. 104.

    Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S, Joachim C, Esiri M, Evetts SG, Rolinski M, Baig F, Ruffmann C, Wade-Martins R, Hu MT, Parkkinen L, Green AJ. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol. 2016;3(10):812–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  105. 105.

    Sano K, Atarashi R, Satoh K, Ishibashi D, Nakagaki T, Iwasaki Y, Yoshida M, Murayama S, Mishima K, Nishida N. Prion-like seeding of Misfolded α-Synuclein in the brains of dementia with Lewy body patients in RT-QUIC. Mol Neurobiol. 2018;55(5):3916–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  106. 106.

    Groveman BR, Orrù CD, Hughson AG, Raymond LD, Zanusso G, Ghetti B, Campbell KJ, Safar J, Galasko D, Caughey B. Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC. Acta Neuropathol Commun. 2018;6(1):7.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  107. 107.

    Manne S, Kondru N, Hepker M, Jin H, Anantharam V, Lewis M, Huang X, Kanthasamy A, Kanthasamy AG. Ultrasensitive detection of aggregated α-Synuclein in glial cells, human cerebrospinal fluid, and brain tissue using the RT-QuIC assay: new high-throughput Neuroimmune biomarker assay for Parkinsonian disorders. J NeuroImmune Pharmacol. 2019.

    PubMed  Article  PubMed Central  Google Scholar 

  108. 108.

    Candelise N, Schmitz M, Llorens F, Villar-Piqué A, Cramm M, Thom T, da Silva Correia SM, da Cunha JEG, Möbius W, Outeiro TF, Álvarez VG, Banchelli M, D'Andrea C, de Angelis M, Zafar S, Rabano A, Matteini P, Zerr I. Seeding variability of different alpha synuclein strains in synucleinopathies. Ann Neurol. 2019;85(5):691–703.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  109. 109.

    Garrido A, Fairfoul G, Tolosa ES, Martí MJ, Green A, Barcelona LRRK2 Study Group. α-Synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson's disease. Ann Clin Transl Neurol. 2019;6(6):1024–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  110. 110.

    van Rumund A, Green AJE, Fairfoul G, Esselink RAJ, Bloem BR, Verbeek MM. α-Synuclein real-time quaking-induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism. Ann Neurol. 2019;85(5):777–81.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  111. 111.

    Kang UJ, Boehme AK, Fairfoul G, Shahnawaz M, Ma TC, Hutten SJ, Green A, Soto C. Comparative study of cerebrospinal fluid α-synuclein seeding aggregation assays for diagnosis of Parkinson's disease. Mov Disord. 2019;34(4):536–44.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  112. 112.

    De Luca CMG, Elia AE, Portaleone SM, Cazzaniga FA, Rossi M, Bistaffa E, De Cecco E, Narkiewicz J, Salzano G, Carletta O, Romito L, Devigili G, Soliveri P, Tiraboschi P, Legname G, Tagliavini F, Eleopra R, Giaccone G, Moda F. Efficient RT-QuIC seeding activity for α-synuclein in olfactory mucosa samples of patients with Parkinson's disease and multiple system atrophy. Transl Neurodegener. 2019;8:24.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  113. 113.

    Watts JC, Giles K, Oehler A, Middleton L, Dexter DT, Gentleman SM, DeArmond SJ, Prusiner SB. Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci U S A. 2013;110(46):19555–60.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  114. 114.

    Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M, Van den Haute C, Melki R, Baekelandt V. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015;552(7556):430–344.

    Google Scholar 

  115. 115.

    Peng C, Gathagan RJ, Covell DJ, Medellin C, Stieber A, Robinson JL, Zhang B, Pitkin RM, Olufemi MF, Luk KC, Trojanowski JQ, Lee VM. Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies. Nature. 2018;557(7706):558–63.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  116. 116.

    Wemheuer WM, Wrede A, Schulz-Schaeffer WJ. Types and strains: their essential role in understanding protein aggregation in neurodegenerative diseases. Front Aging Neurosci. 2017;9:187.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  117. 117.

    Cuillé J, Chell PL. La maladie dite tramblante du mouton est-ell inoculable? C.R. Acad Sci. 1936;208:1552–4.

    Google Scholar 

  118. 118.

    Pattison IH, Millson GC. Scrapie produced experimentally in goats with special reference to the clinical syndrome. J Comp Pathol. 1961;71:101–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  119. 119.

    Bessen RA, Kocisko DA, Raymond GJ, Nandan S, Lansbury P, Caughey B. Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature. 1995;475(6533):698–700.

    Article  Google Scholar 

  120. 120.

    Safar J, Wille H, Itri V, Groth D, Serban H, Torchia M, Cohen FE, Prusiner SB. Eight prion strains have PrP (Sc) molecules with different conformations. Nat Med. 1998;4(10):1157–65.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  121. 121.

    Thakur P, Breger LS, Lundblad M, Wan OW, Mattsson B, Luk KC, Lee VMY, Trojanowski JQ, Björklund A. Modeling Parkinson's disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain. Proc Natl Acad Sci U S A. 2017;114(39):E8284–93.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  122. 122.

    Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002;34(4):521–33.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  123. 123.

    Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, Berry DB, Patel S, Oehler A, Lowe JK, Kravitz SN, Geschwind DH, Glidden DV, Halliday GM, Middleton LT, Gentleman SM, Grinberg LT, Giles K. Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A. 2015;112(38):E5308–17.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  124. 124.

    Bousset L, Pieri L, Ruiz-Arlandis G, Gath J, Jensen PH, Habenstein B, Madiona K, Olieric V, Böckmann A, Meier BH, Melki R. Structural and functional characterization of two alpha-synuclein strains. Nat Commun. 2013;4:2575.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  125. 125.

    Kim C, Lv G, Lee JS, Jung BC, Masuda-Suzukake M, Hong CS, Valera E, Lee HJ, Paik SR, Hasegawa M, Masliah E, Eliezer D, Lee SJ. Exposure to bacterial endotoxin generates a distinct strain of α-synuclein fibril. Sci Rep. 2016;6:30891.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  126. 126.

    Fagerqvist T, Näsström T, Ihse E, Lindström V, Sahlin C, Tucker SM, Kasaryan A, Karlsson M, Nikolajeff F, Schell H, Outeiro TF, Kahle PJ, Lannfelt L, Ingelsson M, Bergström J. Off-pathway α-synuclein oligomers seem to alter α-synuclein turnover in a cell model but lack seeding capability in vivo. Amyloid. 2013;20(4):233–44.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  127. 127.

    Pham CL, Leong SL, Ali FE, Kenche VB, Hill AF, Gras SL, Barnham KJ, Cappai R. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner. J Mol Biol. 2009;387(3):771–85.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  128. 128.

    Näsström T, Fagerqvist T, Barbu M, Karlsson M, Nikolajeff F, Kasrayan A, Ekberg M, Lannfelt L, Ingelsson M, Bergström J. The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of α-synuclein oligomers with distinct biochemical, morphological, and functional properties. Free Radic Biol Med. 2011;50(3):428–37.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  129. 129.

    Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol. 2008;15(6):558–66.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

Download references


The project was supported by the German Academic Exchange Service (DAAD) project 57421248, by the Alzheimer Forschung Initiative (AFI) project 17022 and the Instituto Carlos III (Miguel Servet programme—CP16/00041) to FL).

Author information




Concept and design: NC, MS, IZ; Writing: NC, MS, IZ; Drafting the review: AR, ES, HV, KT, MC, SZ, AVP, FL. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Matthias Schmitz.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Candelise, N., Schmitz, M., Thüne, K. et al. Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays. Transl Neurodegener 9, 5 (2020).

Download citation


  • RT-QuIC
  • α-Synucleinopathies
  • Protein misfolding
  • Protein strains